降低烟草相关肺癌风险:无卡瓦醉椒素AB-Free卡瓦随机临床试验研究方案
本研究为随机对照试验方案,计划入组80名每日吸烟至少10支的成年人,按1:1随机分配至安慰剂组或无AB-Free卡瓦组,暴露4周,共6次访视(第0、1、2、4、8、12周),评估依从性及对烟草依赖、烟草使用和肺癌发生生物标志物的潜在影响。
要点
- 每日吸烟≥10支的成年人按1:1随机接受安慰剂或无AB-Free卡瓦,暴露4周。
- 共6次访视(第0、1、2、4、8、12周),评估依从性与潜在问题。
- 探索性目的包括对烟草使用、烟草依赖及烟草诱导癌变的抑制作用。
核心结论
- 该试验将评估无AB-Free卡瓦在无戒烟意愿的当前吸烟成年人中的依从性。
- 探索性目的包括无AB-Free卡瓦干预能否减少烟草使用和烟草依赖。
- 探索性目的包括无AB-Free卡瓦使用是否抑制烟草诱导的癌变。
- 探索性目的包括基于机制的无创生物标志物在精准无AB-Free卡瓦干预中的潜力。
- 作者预期阳性结果将有望有效降低吸烟率和烟草相关疾病。
研究设计与样本
- 随机对照试验,计划入组80名当前每日吸烟至少10支的成年人。
- 按1:1随机分配至安慰剂组和无AB-Free卡瓦组,暴露4周。
- 共6次访视(第0、1、2、4、8、12周),评估依从性和潜在问题。
- 参与者在其初级保健诊所就诊期间入组。
- 试验注册于ClinicalTrials.gov,标识号NCT05081882,注册日期2021年10月18日。
临床怎么用
- 作者认为初级保健机构在烟草相关疾病筛查、咨询和早期干预中起关键作用。
- 作者指出大多数吸烟成年人每年就诊于其医生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tobacco use is the leading cause of many preventable diseases, resulting in premature death or disease. Given that the majority of adult who smoke want to stop, this health burden could be significantly reduced if the success rate of tobacco cessation can be improved. In addition, most adults planning to quit were interested in trying complementary approaches to facilitating tobacco cessation, which is currently lacking. Therefore, there is an unmet and urgent need for novel interventions to improve the success of tobacco cessation. If such an intervention can reduce tobacco-associated lung carcinogenesis, that will be more desirable. The goal of this project is to develop a safe and effective kava-based intervention to enable tobacco cessation and reduce lung cancer risk, which will improve the health of smokers. METHODS: A randomized controlled trial will enroll 80 adults who currently smoke at least 10 cigarettes daily and randomize 1:1 into the placebo and AB-free kava arms, being exposed for 4 weeks, with a total of six visits (weeks 0, 1, 2, 4, 8, and 12) to evaluate the compliance and potential issues of AB-free kava use among the participants, explore the potential effect of the AB-free kava intervention on tobacco dependence, tobacco use, and lung carcinogenesis biomarkers. Participants will be enrolled during their primary care clinic visit. DISCUSSION: Primary care settings play a critical role in tobacco-related disease screening, counseling, and early intervention, as the majority of adults who smoke visit their physicians annually. Building upon our promising pilot human trial results in conjunction with ample compelling lab animal results, and consistent with evidence of kava's benefits from epidemiological data, this trial will evaluate the compliance of AB-free kava among adults who currently smoke with no intention to quit. The other exploratory aims include (1) whether AB-free kava intervention can reduce tobacco use and tobacco dependence; (2) whether AB-free kava use suppresses tobacco-induced carcinogenesis; and (3) the potential of the mechanism-based noninvasive biomarkers in precision AB-free kava intervention. The positive results from this study are expected to provide a great opportunity to effectively reduce smoking rates and tobacco-related diseases. TRIAL REGISTRATION: ClinicalTrials.gov with the identifier: NCT05081882. Registered on October 18, 2021.
引用
- Xing C, Malaty J, Malham MB, et al. Reducing tobacco-associated lung cancer risk: a study protocol for a randomized clinical trial of AB-free kava. Trials. 2023. PMID: 36653872. doi:10.1186/s13063-023-07081-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。